Geneos Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.7K | Hold |
215
| – | – | ﹤0.01% | 1966 |
|
|
2026
Q1 | $10.2K | Sell |
215
-100
| -32% | -$5.27K | ﹤0.01% | 1979 |
|
|
2025
Q4 | $16.5K | Sell |
315
-100
| -24% | -$5.99K | ﹤0.01% | 1802 |
|
|
2025
Q3 | $26.9K | Hold |
415
| – | – | ﹤0.01% | 1609 |
|
|
2025
Q2 | $20.2K | Buy |
415
+10
| +2% | +$387 | ﹤0.01% | 2028 |
|
|
2025
Q1 | $13.8K | Hold |
405
| – | – | ﹤0.01% | 2115 |
|
|
2024
Q4 | $15.9K | Sell |
405
-100
| -20% | -$4.72K | ﹤0.01% | 1837 |
|
|
2024
Q3 | $23.7K | Sell |
505
-375
| -43% | -$19K | ﹤0.01% | 1501 |
|
|
2024
Q2 | $47.5K | Buy |
880
+9
| +1% | +$521 | ﹤0.01% | 1089 |
|
|
2024
Q1 | $59.4K | Buy |
871
+311
| +56% | +$22.3K | ﹤0.01% | 1011 |
|
|
2023
Q4 | $35.1K | Hold |
560
| – | – | ﹤0.01% | 1178 |
|
|
2023
Q3 | $25.4K | Sell |
560
-1
| -0.2% | -$52 | ﹤0.01% | 1291 |
|
|
2023
Q2 | $31.5K | Buy |
561
+355
| +172% | +$20.1K | ﹤0.01% | 1231 |
|
|
2023
Q1 | $9.32K | Hold |
206
| – | – | ﹤0.01% | 1573 |
|
|
2022
Q4 | $8.37K | Sell |
206
-335
| -62% | -$17.8K | ﹤0.01% | 1579 |
|
|
2022
Q3 | $35K | Sell |
541
-590
| -52% | -$42.8K | ﹤0.01% | 1142 |
|
|
2022
Q2 | $72K | Sell |
1,131
-7
| -0.6% | -$412 | ﹤0.01% | 1128 |
|
|
2022
Q1 | $71K | Sell |
1,138
-644
| -36% | -$40.4K | ﹤0.01% | 1219 |
|
|
2021
Q4 | $135K | Buy |
1,782
+15
| +0.8% | +$1.31K | 0.01% | 1057 |
|
|
2021
Q3 | $196K | Buy |
1,767
+1
| +0.1% | +$126 | 0.01% | 865 |
|
|
2021
Q2 | $275K | Buy |
1,766
+65
| +4% | +$7.91K | 0.01% | 725 |
|
|
2021
Q1 | $223K | Hold |
1,701
| – | – | 0.01% | 920 |
|
|
2020
Q4 | $194K | Buy |
1,701
+580
| +52% | +$68.6K | 0.01% | 836 |
|
|
2020
Q3 | $94K | Hold |
1,121
| – | – | ﹤0.01% | 963 |
|
|
2020
Q2 | $82K | Buy |
1,121
+400
| +55% | +$23.4K | ﹤0.01% | 1006 |
|
|
2020
Q1 | $30K | Sell |
721
-400
| -36% | -$20.7K | ﹤0.01% | 1335 |
|
|
2019
Q4 | $73K | Buy |
1,121
+100
| +10% | +$5.46K | ﹤0.01% | 1069 |
|
|
2019
Q3 | $43K | Hold |
1,021
| – | – | ﹤0.01% | 1259 |
|
|
2019
Q2 | $48K | Hold |
1,021
| – | – | ﹤0.01% | 1209 |
|
|
2019
Q1 | $36K | Hold |
1,021
| – | – | ﹤0.01% | 1296 |
|
|
2018
Q4 | $27K | Buy |
1,021
+821
| +411% | +$28.5K | ﹤0.01% | 1367 |
|
|
2018
Q3 | $8K | Buy |
+200
| New | +$10.5K | ﹤0.01% | 1909 |
|
|
2018
Q2 | – | Sell |
-548
| Closed | -$25K | – | 2265 |
|
|
2018
Q1 | $25K | Buy |
+548
| New | +$22.6K | ﹤0.01% | 1293 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Geneos Wealth Management's CRSP Position: Q2 2026 in Review
Geneos Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 215 shares worth $11.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1966.
Geneos Wealth Management first reported a position in CRSP in Q1 2018 and has held it in 33 quarters since. The position peaked at $275K in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- Geneos Wealth Management held 215 shares of CRISPR Therapeutics worth $11.7K as of Q2 2026.
- Geneos Wealth Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
- CRISPR Therapeutics made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #1966 holding.
- Geneos Wealth Management first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 33 quarters since.
- Geneos Wealth Management's CRISPR Therapeutics position peaked at $275K in Q2 2021.
- 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.